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CausalityGenome-scale mechanistic models of pathways are gaining importance for genomic data interpretation
because they provide a natural link between genotype measurements (transcriptomics or genomics data)
and the phenotype of the cell (its functional behavior). Moreover, mechanistic models can be used to pre-
dict the potential effect of interventions, including drug inhibitions. Here, we present the implementation
of a mechanistic model of cell signaling for the interpretation of transcriptomic data as an R/Bioconductor
package, a Cytoscape plugin and a web tool with enhanced functionality which includes building inter-
pretable predictors, estimation of the effect of perturbations and assessment of the effect of mutations in
complex scenarios.
 2021 The Author(s). Published by Elsevier B.V. on behalf of Research Network of Computational and
Structural Biotechnology. This is an open access article under the CC BY-NC-ND license (http://creative-
commons.org/licenses/by-nc-nd/4.0/).1. Introduction
Mechanistic models of signaling pathways provide a natural
bridge from variations in genotype (at the scale of gene activity
or integrity) to variations in phenotype (at the scale of cells, tissues
or organisms) [1]. They are built over graphs that represent the
biological knowledge of the complex functional relationships
among proteins within the cell, as described in repositories such
as KEGG [2], Reactome [3], WikiPathways [4], or other more spe-
cialized, such as Disease Maps [5]. Specifically, they provide a con-
ceptual framework for the interpretation of gene expression or
genomic variation data and their consequences over downstream
processes and phenotypic responses, such as cell proliferationand death, which are particularly relevant for studying disease pro-
gression or drug response [6]. Mechanistic models have success-
fully been used to understand the disease mechanisms behind
different cancers [7,8] (including neuroblastoma [9,10] and
glioblastoma [11]) rare diseases [12,13], complex diseases such
as diabetes [14] or obesity [15], the mechanisms of action of drugs
[16] or gender-specific effects of drugs in cancer [17]. In addition to
diseases, other scenarios have been studied, such as the molecular
mechanisms of death and the post-mortem ischemia of a tissue
[18] or the effects of nanoplastics on embryos and human induced
pluripotent stem cells [19].
One of the most important aspects of mechanistic models is
that they convey the notion of causality and can, therefore, be used
to predict the downstream consequences of perturbations of speci-
fic conditions [20]. Thus, the possibility of simulating the effect of a
drug allowed a systematic in silico drug repurposing experiment in
Fanconi Anemia [21] in which some of the drugs predicted were
further validated [22]. Also recently, all the targeted drugs cur-
rently in clinical trials for testing treatment and prevention of
COVID-19 [23] were predicted by means of a mechanistic model
[24] of the COVID-19 disease map [25]. Another interesting
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drug inhibitions at single-cell level uncovers the molecular basis
of the generation of resistance to bevacizumab in glioblastomas
[11]. The effect of mutations can also be simulated with mechanis-
tic models, which demonstrated that mechanistic models are
excellent tools to interpret the consequences of complex muta-
tional patterns in diseases such as diabetes [14].
In spite of the usefulness of this innovative approach, the lack of
user-friendly bioinformatic tools has hindered the extensive appli-
cation of mechanistic models to unravel the full potential of inter-
pretation in transcriptomic or genomics experiments. Here we
present three implementations of the HiPathia [7] algorithm, a
mechanistic model of signaling pathways which provides user-
friendly interpretations of the downstream consequences that
gene expression levels have over signaling circuits and, ultimately,
over cell functionality. In a recent benchmarking, this algorithm
has demonstrated to outperform other competing alternatives for
modeling signaling pathways [6] (See Supplementary Fig. 1). The
HiPathia algorithm is available in three different formats: i) as an
R/Bioconductor package for experienced users interested in a pro-
grammatic use of the algorithm, as a plugin for the Cytoscape [26]
community, which offer a graphic environment for end users, and
iii) as a web tool with a dynamic intuitive graphical interface, use-
ful for inexperienced users. The web interface implements extra
functionalities beyond the classical differential circuit activity for
two-class comparisons, that include the analysis of the impact of
simulated interventions (inhibitions, namely knock-outs or
knock-downs, over-expressions, etc.) over the activity of the path-
ways [20] and the evaluation of the potential consequences of
mutations over signaling modulation [14]. Moreover, the web
interface allows building predictors using signaling circuit activi-
ties as features. Interestingly, the features selected by the predictor
as relevant for class discrimination provide at the same time valu-
able insights on the molecular mechanisms that explain the differ-
ences between the conditions to discriminate, namely diseases,
drug action mechanisms, etc.2. Material and methods
2.1. The Hipathia mechanistic model
The Hipathia mechanistic model allows modeling the behavior
of signaling pathways, described as directed graphs that connect
receptor proteins to effector proteins through a chain of activations
and inhibitions exerted by intermediate proteins. However, path-
ways available in the different repositories (KEGG [2], Reactome
[3], WikiPathways [4], etc.) describe multifunctional entities with
often opposite functionalities (e.g. cell death and cell survival are
triggered by the apoptosis pathway, depending on what signalingFig. 1. Example of a signaling circuit composed by a receptor protein, A, 5 proteins that
protein, G, that ultimately triggers a function. The table represents the normalized gene e
starting with a hypothetical signal of 1 renders a final intensity signal of 0.452 in the ex
2969circuits are transducing the signal). Therefore, to model in detail
the specific cell functionalities, any pathway is first decomposed
into circuits (Supplementary Fig. 2). Signaling circuits constitute
the elementary functional entities that connect one or more recep-
tors to one effector protein, which ultimately triggers specific func-
tions in the cell. The Hipathia algorithm simulates the propagation
of the signal considering the level of activity of the proteins that
compose the circuit. In this way, different direct (phosphopro-
teomic) or indirect (protein or gene expression levels) measure-
ments of protein activity can be converted into signaling circuit
activities, and consequently, functional profiles of cell activity
[7]. In order to be active and therefore transduce the signal to ulti-
mately trigger a function, a circuit requires of the simultaneous
presence of the chain of proteins that connect the receptor to the
effector, as well the absence of inhibitor proteins that may compro-
mise the transduction of the signal along the circuit. Fig. 1 exempli-
fies how the signal is transduced across a circuit. In response to
specific stimuli (with an arbitrary value of 1), the input node gen-
erates signals that are transduced along the pathway following the
direction of the interactions until it reaches an output node which
triggers some specific cell functionality as response. For each node
n within the signal transduction circuit, the signal is propagated
along the nodes according to the following recursive rule:








1 Sið Þ ð1Þ
where Sn is the signal intensity for the current node n, vn is its
normalized gene expression value, A is the set of activation signals
(sa), arriving to the current node from activation edges, Iis the set of
inhibitory signals (si) arriving to the node from inhibition edges.
See [7] for details. Causality in a holistic context is conveyed by
the fact that the expression levels will determine the ultimate
functional consequences, following the rules imposed by the signal
transduction circuit. Moreover, changes in the activity of the nodes
will be reflected (or remain unnoticed) in the last effector node,
depending on the topology of each circuit.
2.2. Pathways modelled, user-defined pathways and imported
pathways
In the three implementations of the current version of Hipathia
more than 8000 circuits have been identified and modeled within a
total of more than 150 KEGG [2] pathways of three species (human,
mouse and rat).
Also, Simple interaction files (SIF), describing the directional
interactions (Activity Flow) among the proteins in the pathway,
along with Attributes files (ATT), containing information on thetransduce the signal B, C, D, E and F, one of them being an inhibitor, and an effector
xpression values. The application of the formula below with the values in the table,
ample.
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models for new, user-defined pathways using the mgi_from_sif
function from the Hipathia Bioconductor package
Thus, pathways from databases that contain Activity Flow struc-
tured interactions such as Omnipath [27] or SIGNOR [28], can
easily be modelled in Hipathia. Moreover, SIF files can also be
extracted from SBML qual files using CaSQ [29], enabling to model
pathways from other repositories.
2.3. Circuit functionality annotation
The default Hipathia circuits are annotated using both Uniprot
[30] and Gene Ontology (GO) [31] annotations associated with
the effector node. This allows obtaining functional profiles in addi-
tion to signaling profiles. User-defined or imported pathways can
be annotated with the dbannot function from the Hipathia Biocon-
ductor package.
2.4. Predictive model
In addition, we have built a prediction tool that makes discrete
class predictors based on circuit signaling activity features, which
can be used for class assignation to unknown samples and to aug-
ment the interpretability of the data. The model is a pipeline com-
posed of three steps: i) feature selection by means of the Least
Absolute Shrinkage and Selection Operator (LASSO) method [32],
ii) a Support Vector Machine (SVM) [33] for predicting the class
of the samples and iii) a cross-validation operator used to select
the best hyperparameters of the methods (the whole procedure
is explained with more detail in the web documentation). Thanks
to this classification pipeline we can predict the class of unknown
samples along with a ranking (using the absolute value of the
LASSO coefficients) of which circuits are more important in
accordance with the classification problem at hand. The SVM has
been implemented using the LIBSVM library [34] by means of the
R interface provided by the package e1071 [35]), whereas the
LASSO is built with the glmnet R package which implements a fast
coordinate descent version of the LASSO [36].
2.5. Implementation
The R/Bioconductor package implements the Hipathia algo-
rithm behind the mechanistic model of cell signaling [7]. The R/
Bioconductor Hipathia application implements the model that
transforms the gene (or protein) expression matrix into a circuit
signaling matrix (Fig. 2A) and only offers the possibility of, given
the meta-information that distinguishes two classes within the
data, carrying out a differential signaling text (Fig. 2B).
This application is the core for the Cytoscape plugin and the
web applications. The Cytoscape plugin, adds the visual represen-
tation to the differential signaling test (Fig. 2C).
The web application uses the R/Bioconductor application as
backend to implement new functionalities in the front-end. These
are: the possibility of obtaining class predictors using circuit activ-
ity profiles as features (Fig. 2D), The estimation of the effect of per-
turbations (e.g. knock-outs, inhibitions, overexpression, drug
effects, etc.) on a given condition (Fig. 2E), and estimating the effect
of loss-of-function (LoF) mutations in the Impact analysis function-
ality (Fig. 2F). The client of the web application has been imple-
mented in JavaScript using the HTML5 and SVG standards and
uses CellMaps [37] libraries for interactive visual representation
of pathways. By default, the web server starts in anonymous mode
for occasional use, but it also allows free user registration. Regis-
tered users can have permanent storage of their data and analyses
done.29702.6. Input data
The Hipathia Bioconductor package, which provides the core
functionality to the web interface and the Cytoscape plugin,
accepts input data in Comma-separated value (CSV) format with
samples as columns and genes/proteins as rows. In order to
Hipathia identify gene or protein names, standard IDs must be
used. The program can deal with more than 20 standard gene or
probe IDs for human, mouse and rat. The data typically comes from
gene expression, measured with any sequencing or microarray
technology, but also proteomics or phosphoproteomic data can
be uploaded. It is assumed that the data has already been normal-
ized for correcting any possible sequencing bias, including batch
effect correction. Like in any methodology based on gene expres-
sion (e.g. conventional differential gene expression tests) the type
of normalization carried out could have an effect of the final
results. There are tools and workflows available for the normaliza-
tion of gene expression data [38]. In the case of proteomic data, the
format requirements are the same. Users of different programs like
Skyline [39] or MaxQuant [40], or commercial software, like Peaks,
ProteomeDiscoverer, etc., have to export the data in text format
(CSV) and normalize them.3. Results and discussion
3.1. Differential signaling activity and visualization of the results
Circuit signaling activity values (Fig. 1A) can be used to conduct
tests that compare two conditions or to obtain correlations with a
continuous variable (Fig. 1B). Hipathia inputs a matrix of normal-
ized gene (or protein) expression profiles of samples belonging to
different classes (defined in the metadata file) and transform it in
the corresponding circuit activity matrix (Fig. 1A). This matrix
can be used to conduct a test of differential activity between sam-
ples belonging to the different groups (Wilcoxon test is used)
whose sign indicates up- or down-regulation of the circuits. In
addition to discrete classes, a continuous value can be associated
to any sample (e.g., the value of a metabolite, a continuous-value
phenotype, etc.) Then, a regression can be conducted to detect cir-
cuits associated to changes in the value measured for each sample.
All the p-values are corrected for multiple testing [41]. The web
interface and the Cytoscape plugin provide an intuitive interface
to indicate the experimental design (paired or unpaired). select
the pathways to be included in the comparison and provide a
visual representation of the results as heatmaps and PCA plots
(Fig. 1B). An interactive graphical view of the pathways analyzed
in which the individual signaling circuits are individualized, high-
lighting those in which significant changes in signaling was found,
along with the downstream functional consequences (Fig. 1C).
The HiPathia documentation presents an interesting example of
differential signaling between the estrogen receptor positive (ER+)
breast cancer patients versus estrogen negative (ER-) ones. A total
of 178 samples of breast cancer tumors were randomly selected
from the dataset available in The Cancer Genome Atlas (TCGA)
and annotated as ER+ and ER- [42]. Gene expression data of the
example was already normalized using trimmed mean of m-
values (TMM) [43], and automatically uploaded in the Hipathia
web server, where the option Differential signaling activity was
chosen.
Gene expression profiles were used to infer signaling activity
profiles that were further subjected to a differential activity con-
trast. As expected, signaling circuits in numerous pathways dis-
played a different activity between ER+ and ER- samples.
Interestingly, most of the circuits of the Estrogen receptor pathway
are downregulated in ER-negative tumors (Fig. 3A). Considering
Fig. 2. HiPathia use and functionalities. A) Transformation of matrices of gene (or protein) expression (activity) into matrices of circuit activities, by decomposing pathways
into circuits. B) Estimation of differential signaling, a core functionality included in the R/Bioconductor Hipathia package. C) Interactive visualization of the circuits
differentially activated, a functionality implemented in the Cypathia (the Cytoscape implementation, as well as in the web implementations. D) Generation of class predictors
based on circuit signaling activity features, and its use for class assignation to unknown samples. E) Estimation of the effect of perturbations (KOs, overexpression, drug
inhibitions, etc.) on the circuits and the downstream functionalities. F) Estimation of the impact of mutations in complex systems, considering its downstream effect on cell
functionality.
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receptors, these results are consistent with prior knowledge on
the insensitivity to estrogens displayed by this pathway [44].
An interesting aspect of the advantages of holistic approaches,
such as the provided bymechanistic models, is illustrated by CREB3
gene that, via several signaling circuits, controls transcription reg-
ulation. Despite CREB3 is upregulated in ER-cancers, which in a
gene-centric analysis would suggest activation of transcription
mediated by estrogens, the holistic analysis of Hipathia ultimately
renders a generalized down-activation of the signaling activity in
the whole Estrogen receptor pathway due to the down-activation
of most of the signaling circuits that activates CREB3 (Fig. 3A).
In the focal adhesion pathway, the activity of proteins involved
in actin polymerization, such as actinin, vinculin, and zyxin, is2971upregulated in ER- tumors. Actin polymerization is involved in cell
migration processes required for metastasis, which explains their
upregulation given that ER- tumors are known to be more prone
to migration and metastasis [45].
This example is available in the Hipathia documentation:
http://hipathia.babelomics.org/doc/doku.php?id=worked_
example_differential_example.
3.2. Predictors based on signaling features
In addition, signaling circuits can be used to build a predictor of
discrete classes (e.g., cancer type, see Fig. 1D). The prediction
option allows building a predictor with the well-known SVM algo-
rithm [33] and later using it to predict class membership for
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as old as the own transcriptomics. One of the most successful deci-
sion support systems in breast cancer, currently known as Mam-
maprint in its commercial implementation, was first proposed
as early as by 2002 [46]. Since then, many endpoint predictors have
been proposed for different cancers [47,48] and have become
mainstream as a decision tool in oncology [49]. Despite the rele-
vance of signaling pathways in the management of cancer is
known for long [50] all the available decision support systems
based on gene expression use individual genes as features. This
hampers the interpretability of the results obtained, given that
genes, out of context, cannot be easily related with the functional-Fig. 3. Pathways showing signaling circuits differentially activated. Effector nodes an
activation and red arrows up-activation A) Estrogen receptor (ER) pathway; B) Focal ad
figure legend, the reader is referred to the web version of this article.)
2972ities they are ultimately triggering. However, if instead of gene
expression levels, the derived signaling circuit activities are used,
the interpretability of the result drastically increases as exempli-
fied in a recent predictor of drug sensitivity [16].
The use of this option can be exemplified by building a predictor
to discriminate between luminal A and luminal B breast cancer
types, which are relevant for the selection of drug treatment
[51]. Again, data is taken from the TCGA breast dataset [42], using
first a subset of 505 samples (335 luminal A and 170 luminal B) for
training the predictor. The accuracy of the prediction is assessed by
cross validation (see the different metrics reported in Fig. 4A). The
features that best discriminate between the response values ared functions affected have been enhanced for clarity. Blue arrows indicate down-
hesion pathway (hsa04510). (For interpretation of the references to colour in this
Fig. 4. Output of the prediction option. A) Metrics for assessment of the predictor accuracy; B) Most relevant features for the predictor. C) Precision Recall curve; D) Receiver
Operator curve; E) probability boxplots.
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ods). Interestingly, the first two more relevant features selected
in the example are signaling circuits of the P53 signaling pathway
(Fig. 4B), with a known central role in breast cancer subtype defi-
nition [52]. Finally, the Precision Recall (Fig. 4C) and Receiver Oper-
ator (Fig. 4D) curves, along with probability boxplots for the test
set (Fig. 4E), for typical train test split scenario are provided. This
functionality is available only in the web interface. An example
for training and testing the predictor is available in the Hipathia
documentation: http://hipathia.babelomics.org/doc/doku.php?
id=worked_example_prediction_train_and_test
3.3. Simulation of signaling perturbation experiments
One of the most interesting functionalities of Hipathia is the
possibility of simulating the effect of different interventions (e.g.
knock-out, over-expression, drug inhibition, etc.) over the activity
of signaling circuits in the pathways, as well as their potential
downstream functional consequences in the cell [20] (Fig. 1E).
Given a specific condition, corresponding to a specific gene expres-
sion profile, knock-outs, knock-downs or different types of inhibi-
tions are simulated by reducing or setting to 0 the expression level
of the gene or interest. Conversely, over-expressions or agonistic
interventions can be simulated by increasing its gene expression
level. Additionally, one or several targeted drugs can be selected
from a list (taken from DrugBank [53]). The effect of the perturba-
tions is simulated and compared to the original conditions, and the
circuits affected are reported.2973Here, the value of this option is demonstrated by means of an
example that focuses on the functional impact that the combined
inhibition of EGFR and c-Raf (RAF1) has over pancreatic tumors.
In the example, the combined effect of erlotinib (a known and
widely used anti-EGFR drug) in combination with the knockdown
of the RAF1 gene is simulated. The drug effect is simulated by mul-
tiplying the expression value in the pancreatic tumor by the activ-
ity factor provided in the settings. To simulate a knockdown, the
activity of the target gene is multiplied by the provided knock-
down factor. In this example, the effect of Erlotinib reduces EGFR
activity to a 10%, while the RAF1 knock-down reduces its activity
to a 1% (see RAF1 knock-down effect simulation in Fig. 5). This
combination has been described to achieve a complete regression
of pancreatic cancer in ductal adenocarcinoma derived xenografts
induced by KRAS mutation [54]. This functionality is available only
in the web interface. An example for training and testing the pre-
dictor is available in the Hipathia documentation: http://hipathia.
babelomics.org/doc/doku.php?
id=worked_example_perturbation_effect.
3.4. Estimation of the impact of mutations on signaling and the
downstream cell functionality
Most predictors of the potential pathogenic consequences of
mutations are actually only predictors of protein LoF mutations
that ignore the actual essentiality of the protein, which is highly
dependent on the complex context of interactions with other pro-
teins. Mechanistic models allow estimating the potential patholog-
Fig. 5. Perturbation effect. Effect of a knock-down in RAF1 gene over the RAS signaling pathway. Effector nodes and functions affected have been enhanced for clarity.
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the signaling circuits and the downstream functional conse-
quences. This holistic approach, in which the effect of gene muta-
tions is assessed in the context of the rest of variation harbored by
the genome, provides an elegant alternative to gene-centric
approaches by offering a systems biology perspective for the inter-
pretation of the genomic variability in complex diseases [14]. In
this option, the notion of causality implemented in the mechanistic
model is again exploited. Knock-outs (KO) are simulated on genes
harboring LoF variants in a reference condition (provided by the
user or selected from the gene expression profiles of normal tissues
available in GTEx [55]). Then the perturbation effect analysis is car-
ried out by comparing the condition with the simulated KOs
against the original condition (Fig. 1F).
An interesting case study is type 2 diabetes (T2D), a highly preva-
lent disease (affects over 8% of the population) with a symptomatol-
ogy that includes several serious comorbilities [56]. Diabetes has a
complex and still not completely known genetic background, diffi-
cult to assess because the disease phenotype is also highly depen-
dent of environmental factors [57]. To exemplify the use of the
Variant interpreter option LoF mutations have systematically been
simulated on genes belonging to pathways related to inflammation,
one of themost relevant consequences of diabetes [58], over expres-
sion profiles of healthy pancreatic donors (taken from GEO reposi-
tory, ID: GSE38642) [59]. Most of the simulated KOs rendered
either non-significant effects on the pathways, or highly significant
effect in genes with almost no polymorphisms (and likely lethal
and consequently not involved in diabetes) [14]. However, a few of
themwere suggestive of being involved in diabetes, as the RAP1GAP
LoF shown in Fig. 6. Since RAP1GAP is an inhibitor of the Rap1 path-
way, the cell functionalities triggered by the circuits that compose
the pathway are predicted to be constitutively activated. The func-
tional consequences of the KO of RAP1GAP vary from up-regulation
of Inflammatory processes, Cell adhesion and Stress response among
others. The results strongly suggest thatRAP1GAPplays an important
role in the control of diabetes-related processes and therefore, LoF2974mutations inactivating such protein will most likely result in an
over-activation of inflammatory response and thus, an increased
risk of developing immune-mediated diabetes [14]. This example
can be found in the Hipathia documentation pages: http://
hipathia.babelomics.org/doc/doku.php?id=workvafin#results_and_
interpretation.4. Discussion
Before highlighting the advantages of mechanistic models for
uncovering disease mechanisms or for predicting the conse-
quences of therapeutic interventions is necessary to remark what
mechanistic models are not. Mechanistic models are not enrich-
ment analysis methods [60], in which a list of genes selected by
any reason (e.g. they were found as differentially expressed in a
given experiment) is tested to discover if some functional labels,
typically gene ontology terms, are significantly more abundant in
them than in the background or in a reference group [61,62]. Hav-
ing a significant enrichment of genes labeled as angiogenesis, for
example, does not indicate whether these genes are promoting or
inhibiting angiogenesis and, moreover, provide no clues on what
would be the consequences of interventions over the genes. Mech-
anistic models are not conventional network analysis methods
[63], where a list of genes is interpreted according to their proxim-
ity or their connectivity within a known network structure, like the
protein–protein-interaction (PPI) network. Although network anal-
ysis methods can be an interesting source of hypotheses, the prox-
imity within a biological network does not necessarily imply a
causal relationship between the proteins involved. Mechanistic
models are built over pathways, which are graphs that represent
the detailed knowledge on the way in which cells respond to dif-
ferent stimuli and behave accordingly. Therefore, they implicitly
convey the notion of causality, because the activity of the different
elements in the model (the genes/proteins) affect the transduction
of the signal, accordingly to the pathway topology, and ultimate
Fig. 6. Holistic assessment of the impact of mutations. LoF of gene RAP1GAP, an inhibitor of the Rap1 pathway, causes a constitutive activation of different inflammatory
processes in the cell. Functions.
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with distinct ways of modeling the transduction of the signal
across pathways, such as TAPPA [64], PWEA [65], CLIPPER [66],
PRS [67], DEGraph [68], DEAP [69], SubSPIA [70], MinePath [71],
or Pathiways [72,73]. A recent benchmark demonstrated that
Hipathia outperformed other alternatives for modeling signaling
pathways [6] (See Supplementary Fig. 1).
Also in the context of signaling, other algorithms focus on dif-
ferent types of relationships among proteins, as in the case of CAR-
NIVAL, which focused on regulatory relationships [74]. A different
approach is used by tools such as CaSQ, that infers Boolean rules
based on the topology and semantics of molecular interaction
maps described in SBML [29], or CellCollective that allow collabo-
rative generation of pathway models [75]. However, these tools do
allow interpreting transcriptomic data but rather describe the the-
oretical behavior of the models associated to the underlying
pathways.
The data used by the tools and methods above cited are, essen-
tially, gene expression data, taken as proxies of the presence of the
activated protein [66,68,72,73,76,77]. Obviously, protein expres-
sion data can be used instead of gene expression and, in theory,
would provide a more accurate approach to the real amount of
activated protein. However, other proteomics data types can be
used in different ways that are beyond the scope of this type of
mechanistic model and obviously beyond the Hipathia functional-
ities. For example, other types of proteomics applications, such as
affinity purification experiments, can be used to infer new pro-
tein–protein interaction connections, or posttranscriptional modi-
fications can be used to elucidate cellular signaling events [78], just
to cite a few different applications.
Here we provide the core functionality of the implementation of
the mechanistic model, along with the most used differential sig-
naling test, implemented in all the tools, and some more function-
alities, that are programmatically easy to implement, using the R/
Bioconductor Hipathia package, by experienced bioinformaticians,
and that have been implemented in the web interface for end
users. These include i) the use of signaling activity profiles as
‘‘mechanistic” features for building a class predictor, ii) the study2975of perturbations in a given condition and iii) the assessment of
the impact of mutations from a holistic perspective.
The notion of using features that are not the initial measure-
ments (gene expression values) but rather a derived value that
accounts for cell functionality of the cell is quite innovative in
the field of prediction. Actually, this idea has been recently pro-
posed calling these features dynamic biomarkers or pathway
biomarkers [9]. However, a comparative study of the performance
of predictors that use signaling profiles versus gene expression
profiles across diseases is out of the scope of the manuscript. Prob-
ably, in diseases with a strong signaling component, like cancer,
they will perform better while in diseases with less representation
in the pathways, the use of gene expression will render a better
prediction. This tool, simply increases the analytic possibilities of
researchers.
In the example presented, the features selected by the LASSO
algorithm that best discriminate between the luminal A and B
groups contain several interesting signaling circuits. Thus, the
two more relevant features are signaling circuits of the P53 signal-
ing pathway (Fig. 4B), known to play a central role in breast cancer
subtype definition, as previously commented [52]. Although an
exhaustive discussion of the results is out of the scope of this
manuscript it is worth mentioning that the rest of circuits selected
are relevant in breast cancer, such as Neutrophin signaling pathway,
active in carcinomas and target of some therapies [79], or RIG-I-like
signaling pathway, also involved in induction of immunogenic
response to breast cancer [80] or RAS signaling pathway known to
be active in breast cancer [81]. Interestingly, circuits selected by
the predictor apparently not related to breast cancer, like the
Amphetamine addiction pathway, have already been described as
involved in breast cancer therapeutic responses [82].
On the other hand, the option that allows the simulation of sig-
naling perturbation experiments represents an extremely valuable
way of predicting the possible effect of drugs (alone or in combina-
tion) and other interventions. To demonstrate the value of this
functionality of the Hipathia web server, and example of the func-
tional impact that the combined inhibition of EGFR and c-Raf
(RAF1) can have on pancreatic tumors was used. This combination
K. Rian, M.R. Hidalgo, C. Çubuk et al. Computational and Structural Biotechnology Journal 19 (2021) 2968–2978has recently been described to produce a complete regression of
pancreatic cancer in ductal adenocarcinoma derived xenografts
induced by KRAS mutation [54].
The simulation of the combination of the inhibitions suggests a
clear impact on cell mechanisms related to several cancer hall-
marks, such as proliferation, apoptosis, and cell adhesion and
motility. Among the pathways dysregulated by the perturbations,
the Ras signaling pathway (KEGG ID: hsa04014), proteoglycans in
cancer (hsa05205), ErbB signaling pathway (hsa04012), and
PI3K/Akt signaling pathway (hsa04151) are especially remarkable.
The dysregulation of these signaling pathways have been described
in pancreatic cancer [83] and the in-silico inhibition globally
reduces the activity and the functions triggered by these, indeed
some targets within them are being used to treat pancreatic
tumors (such as EGFR, KRAS, TGFB, NFKB, MEK1). Focusing on the
Ras signaling pathway (hsa04014), three circuits appear as inhibited
by the knock-down of c-Raf: i) the ELK-1 circuit, which is generally
activated in pancreatic cancer [84], ii) the ETS-1 circuit, given that
the ETS Proto-Oncogene family (ETS) has been linked to pancreatic
cancer progression and, specifically, ETS-1 has been described as
potential targets reducing angiogenesis and progression in pancre-
atic cancer [85,86], and iii) the PLA2G4B circuit, with the PLA2G4B
gene highly expressed in the pancreas, and been this gene
described to modulate the sensitivity of pancreatic cancer cells to
chemoradiation treatment [87]. Among the most represented
effector genes affected by the knock-down simulation, the roles
of PLA2G4B, MAPK1, CDKN1A, ELK1, PRKCA, and CAMK2A in pro-
cesses such as signal transduction, calcium metabolism, and cell
cycle regulation must be highlighted. These mechanisms have been
highly related to cell proliferation and cancer progression, there-
fore inactivating the circuits that trigger these effectors would
result in a potential reduction of cancer prognosis, consistent with
results recently described [54].
5. Conclusions
The mechanistic model implemented in the Hipathia algorithm
enables interactive and intuitive evaluation of the impact of gene
perturbations on signal transduction from a mechanistic perspec-
tive and, consequently, on cell functionality that ultimately deter-
mine the phenotype. Here we provide a Bioconductor/R package,
along with two user-friendly interfaces, for enabling and facilitat-
ing the use of the HiPathia mechanistic model to the scientific
community. The web interface implements new functionalities
taking advantage of the availability of the core functionality pro-
vided by the mechanistic model.
6. Availability
The Bioconductor package is available in the Bioconductor site:
https://bioconductor.org/packages/release/bioc/html/hipathia.
html.
Documentation on the use of the Hipathia Bioconductor pack-
age can be found at: https://bioconductor.org/packages/release/
bioc/manuals/hipathia/man/hipathia.pdf
The Cytoscape plugin is available in the Cytoscape site: http://
apps.cytoscape.org/apps/cypathia.
The web server is available at: http://hipathia.babelomics.org/
The documentation of the Hipathia web server is available at:
http://hipathia.babelomics.org/doc/doku.php.
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